COMMUNIQUÉS West-GlobeNewswire

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
26/09/2019
All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October Conference call and [...]
Arbutus to Participate in Upcoming Investor Conferences
26/09/2019
WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be [...]
SI-BONE, Inc. Announces Publication of Five-Year Prospective Study Results on 103 Patients Treated with Triangular Titanium iFuse Implant System
26/09/2019
Long-term follow-up results show excellent durability of clinical responses and positive radiographic outcomes for SI joint fusion using triangular titanium implants SANTA CLARA, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE [...]
SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 3, 2019
26/09/2019
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, [...]
U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile
26/09/2019
$14 million in non-dilutive capital added by year end RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the U.S. Department of Health and [...]
Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
26/09/2019
REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzgerald Global Healthcare [...]
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
26/09/2019
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration
26/09/2019
EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application ( [...]
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
26/09/2019
SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl [...]
ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019
26/09/2019
YONKERS, N.Y., Sept. 26, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins [...]
OptiNose Announces License Agreement Related to ONZETRA XSAIL
26/09/2019
YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose , Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the [...]
EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
26/09/2019
WATERTOWN, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today [...]
Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019
26/09/2019
Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical group focused on building quality cancer [...]
Precision BioSciences to Present at Upcoming Industry and Investor Conferences
26/09/2019
Company to Participate in the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa, Chardan Genetic Medicines Conference and Jefferies Gene Therapy Summit DURHAM, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE [...]
Treos Bio Reports Updated Positive Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer
26/09/2019
The company presents four scientific posters on its proprietary platform technology at the 2019 ESMO Annual Congress LONDON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Treos Bio Limited, which is developing personal cancer [...]
Demant A/S: Estimated financial impact of IT incident reflected in outlook
26/09/2019
Company announcement no 2019- 11 26 September 2019 Estimated financial impact of IT incident reflected in outlook As previously communicated in Company announcements on 3, 4 and 17 September, the Demant Group [...]
Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial
26/09/2019
Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial Herantis Pharma Plc Company release 26 September 2019 at 9:00 AM Herantis Pharma Plc (“Herantis” or “Company”) announced today an update [...]
Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019
26/09/2019
EVENTS IN FIRST QUARTER Oasmia presented results from two clinical studies of Docecal in patients with metastatic breast cancer The Board of Directors appointed a special examiner to give all shareholders basis for [...]
ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy
26/09/2019
The Company has passed the Last Patient Last Visit (LPLV) milestone in the pivotal gp-ASIT+™ Phase III trial and remains on track to deliver primary efficacy results in December 2019. ASIT biotech is collaborating with [...]

Pages